Andrew ElBardissi, M.D. Named to NeoChord Board of Directors

June 2017


First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation;

November 9, 2016

click for release

NeoChord passes 500 patient treatment milestone follow-up data on 127 patients out to two years presented at EACTS;

October 28, 2016

click for release

NeoChord announces appointment of Alex Jonkers as VP of European Commercial Sales and milestone of over 400 patients treated with the DS1000 System;

May 5, 2016

Click for Release

NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation;

May 13, 2016

Click for Release